No survival benefit with androgen suppression: study
In a retrospective cohort study of 15,000 newly diagnosed men, the researchers found no significant differences in risk of all-cause mortality, prostate cancer-specific mortality or cardiovascular mortality between those receiving PADT and those not receiving it.
They found a slightly reduced risk of death in men at high risk of cancer progression and a slightly raised risk of death among men with low risk disease.
Adverse effects of the therapy included cognitive impairment and diabetes.
J Clin Oncology 2014; online